低分子肝素抗凝用于溃疡性结肠炎伴血压异常患者的临床观察  

Clinical study of low molecular weight heparin anticoagulation applied in the treatment of patients with ulcerative colitis complicated with abnormal blood pressure

作　　者：白延平[1] 刘智娜[2] 高智耀[1] 王晨霞[1] 

机构地区：[1]延安大学附属医院心内科,陕西延安716000 [2]延安大学附属医院麻醉科,陕西延安716000

出　　处：《结直肠肛门外科》2016年第4期384-387,共4页Journal of Colorectal & Anal Surgery

摘　　要：目的观察低分子肝素抗凝用于溃疡性结肠炎(UC)伴血压异常患者的临床效果。方法将2013年8月至2015年8月来我院就诊的88例溃疡性结肠炎伴血压异常患者随机分为观察组与对照组(各44例),两组均采取美沙拉嗪+双歧杆菌四联活菌片常规治疗,进行非药物控压,观察组另外给予低分子肝素抗凝治疗,比较两组临床疗效、疾病活动指数(DAI)评分及肠黏膜组织学评分,并进行肠黏膜组织微血栓检测,记录两组用药期间用药安全性。结果观察组总有效率为97.7%,显著优于对照组(77.3%),差异有统计学意义(P<0.05);观察组DAI评分、肠黏膜组织学评分与治疗前及对照组治疗后同时点比较较低,差异有统计学意义(P<0.05);观察组治疗后肠黏膜组织微血栓阳性率较治疗前及对照组治疗后显著较低,差异有统计学意义(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论低分子肝素抗凝可提高UC的临床疗效,其机制考虑与改善凝血有关,且用药安全性较高,临床应用价值较高。Objective To study the clinical application of low molecular weight heparin anticoagulation in patients with ulcerative colitis（UC） complicated with abnormal blood pressure.Methods Eighty-eight patients with UCcomplicated with abnormal blood pressure were randomized into observation group and control group. Both groups were treated with mesalazine and Bifidobacterium tetravaccine tablets（live）, and non-drug pressure control was performed. The observation group wally treated with low molecular weight heparin（LMWH）. The clinical efficacy, disease activity index（DAI） score and intestinal mucosal histology score were compared between the two groups., and the intestinal mucosal tissue microthrombus detection was performed.The safety of drug use was recorded during medication.Results The clinical efficacy of the observation group was significantly better than that of the control group（P〈0.05）. Observation group DAI score, intestinal mucosal histology score and treatment before and after treatment at the same time point was lower, the difference was statistically significant（P〈0.05）.The positive rate of intestinal mucosal tissue microthrombus detection in the observation group was significantly lower than that before treatment and that in the control group after treatment（P〈0.05）.There was no significant difference in the incidence of adverse reactions between the two groups（P〉0.05）.Conclusion Low molecular weight heparin anticoagulation can improve the clinical curative effect of UC. The mechanism may be related to the improvement of coagulation, andsafety of drug use is high. Higher clinical value.

关 键 词：低分子肝素 溃疡性结肠炎 血压 

分 类 号：R574.62[医药卫生—消化系统]